Bionanao Genomics Inc (BNGO)

[Up/DownTrader]

REPEAT WARNING! The 'WHALES' are NOT quite finished with their 1-5-21 morning BREAKFAST of (delicious) BNGO feeding!!! LOOK OUT!!! (Notice that nasty MM dude with that harpoon????? HA-HA-HA!!!)

We reported last week on Praxis' CAP/CLIA diagnostic test with Saphyr. Next week its founder Dr. Peter Nagy will present on how Saphyr has solved undiagnosed genetic disease cases. Register now to join our Next-Gen Cyto Symposium on Monday Jan 11: https://t.co/31WGmCYsCl $BNGO pic.twitter.com/t6uF97JW0q

— Bionano (@bionano) January 4, 2021

We will show more undiagnosed disease cases being solved at our symposium on Mon Jan 11! Dr. Hayk Barseghyan from Children’s National Medical Center will present how they solved complex genetic disorders & disorders of sex development using Bionano. https://t.co/lm5DJBzshJ $BNGO pic.twitter.com/IohZhFCD6e

— Bionano (@bionano) January 4, 2021

https://finance.yahoo.com/news/bionano-genomics-publishes-study-autism-130000510.html

https://seekingalpha.com/article/4397101-exuberance-over-good-news-drives-bionano-genomics-wild-week

https://www.investorsobserver.com/news/stock-update/bionano-genomics-inc-bngo-up-103-81-in-premarket-trading

https://www.nasdaq.com/articles/pre-market-movers-in-healthcare-sector%3A-ocgn-bngo-jagx-immp-slls...-2021-01-04

https://www.globenewswire.com/news-release/2021/01/04/2152632/0/en/Bionano-Genomics-Publishes-Study-on-Autism-Risk-Genes-After-Detailed-Analysis-of-The-Genome-of-Professor-Temple-Grandin-Who-Has-Brought-Awareness-to-Autism-Spectrum-Disorder-Throug.html

https://www.benzinga.com/news/21/01/19002793/why-calithera-bionano-genomics-and-more-are-moving-today

https://www.fool.com/investing/2021/01/04/why-bionano-genomics-stock-skyrocketed-more-than-1/

"Bionano's optical genome mapping platform, Saphyr, has been shown to be more effective at finding structural variants than its competitors. It's also significantly more cost-effective. For these reasons, analysts expect Saphyr to gain broader adoption in genome sequencing and research applications. Maxim Group analyst Jason McCarthy goes so far as to say that "Saphyr has the potential to change the clinical diagnostic landscape," due in part to its time, labor, and cost efficiencies. McCarthy also believes Saphyr could generate more informative diagnostic results. In turn, he sees rising Saphyr usage and increased testing helping to fuel Bionano's revenue growth."